Should You Buy Bioceres Crop Solutions Corp (BIOX) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
0.840
1 Day change
-13.43%
52 Week Range
7.120
Analysis Updated At
2026/01/28
BIOX is not a good buy right now for a beginner long-term investor with $50k–$100k who doesn’t want to wait for an ideal entry. The stock is in a clear downtrend (bearish moving averages and negative MACD), is sitting right on key support (~$1.14), and the biggest fundamental overhang is event-driven (creditor litigation and potential forced asset sale). With no Intellectia buy signals today and weak recent revenue growth, the risk/reward is unattractive at this moment—best decision is to hold/avoid new buying now.
Technical Analysis
Trend and momentum are bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. MACD histogram is negative (-0.00473) but contracting, suggesting downside momentum is easing (possible stabilization) rather than a confirmed reversal. RSI(6) is 32.4, near oversold territory, which can lead to short bounces but is not a reliable long-term buy signal by itself. Price ($1.14) is essentially at S1 support (1.141); a clean break below points to the next support near S2 (1.075). Upside levels to reclaim for trend improvement: Pivot 1.248, then R1 1.355.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Open interest is extremely call-heavy (put/call OI = 0.01), which can look bullish, but today’s options volume is effectively zero, indicating very thin/illiquid options activity and weak real-time sentiment confirmation. Implied volatility is elevated (30D IV ~74.6) but well below the very high short-term IV averages shown (5D/10D IV averages much higher), implying volatility expectations have been coming down rather than rising into a fresh bullish catalyst.
Technical Summary
Sell
10
Buy
6
Positive Catalysts
Upcoming earnings on 2026-02-10 (pre-market) can act as a catalyst if results/forward commentary stabilize the story.
Gross margin improved to 46.67% in 2026/Q1 (+17.38% YoY), showing some operational improvement despite revenue pressure.
MACD downside momentum is contracting and RSI is near oversold, which can support a short-term stabilization/bounce (not a confirmed trend reversal).
Neutral/Negative Catalysts
Litigation/creditor situation: recent court ruling against Bioceres (per analyst commentary) increases risk of a credit sale process for Pro Farm assets, which could damage operations.
Revenue decline: 2026/Q1 revenue down -16.39% YoY, which is a negative growth signal.
Technical downtrend remains intact (bearish MA stack); support is being tested around ~$1.14 and a breakdown opens room toward ~$1.
Options market is illiquid (near-zero volume), reducing the usefulness of options sentiment and making the stock more prone to gaps.
Financial Performance
Latest quarter: 2026/Q1. Revenue fell to 77,435,995 (-16.39% YoY), indicating top-line contraction. Profitability improved modestly: net income was still negative (-7,327,885) but improved (+15.05% YoY), and EPS improved to -0.12 (+20% YoY). Gross margin rose to 46.67% (+17.38% YoY), a notable positive, but it hasn’t translated into positive earnings yet and the declining revenue keeps overall fundamentals pressured.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent analyst actions are negative-to-cautious: Canaccord maintained a Hold rating but cut the price target twice (from $2.50 → $2.25 on 2025-11-14, then $2.25 → $2.00 on 2026-01-02). Wall Street pro view (based on provided notes): Pros—management execution on margins/expenses/working capital and improving margin profile. Cons—lower revenue/EBITDA, seed business unwind impacting revenue recognition near-term, and heightened risk from the creditor litigation and potential asset sale. Net takeaway: professionals are not recommending aggressive buying; they are staying on the sidelines (Hold) while key risks resolve.
Wall Street analysts forecast BIOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOX is 2 USD with a low forecast of 2 USD and a high forecast of 2 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BIOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOX is 2 USD with a low forecast of 2 USD and a high forecast of 2 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 0.968
Low
2
Averages
2
High
2
Current: 0.968
Low
2
Averages
2
High
2
Canaccord
Austin Moeller
Hold
downgrade
$2
AI Analysis
2026-01-02
Reason
Canaccord
Austin Moeller
Price Target
$2
AI Analysis
2026-01-02
downgrade
Hold
Reason
Canaccord analyst Austin Moeller lowered the firm's price target on Bioceres to $2 from $2.25 and keeps a Hold rating on the shares. On December 18, New York's Supreme Court ruled against Bioceres in ongoing litigation with the company's creditors, the analyst tells investors in a research note. The firm says that with the judge's non-final verdict determined, a credit sale process of Bioceres' Pro Farm assets will likely now ensue. It believes the process could be damaging to the company's operations.
Canaccord
Hold
downgrade
2025-11-14
Reason
Canaccord
Price Target
2025-11-14
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Bioceres to $2.25 from $2.50 and keeps a Hold rating on the shares. The firm reported lower Q1 revenues and adjusted EBITDA. The company has executed well on management's previously stated business priorities, including efforts to improve the business's margin profile, reduce operating expenses and better manage WC. Management cited expectations for the sustained unwinding of the seed business to temporarily lower upfront revenue recognition for the next two quarters in the segment.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIOX
